Boulevard starts up with $65M to pursue targeted autoimmune drugs
Co-founded by pioneering researcher Georg Schett and ex-Sanofi CSO Frank Nestle, the startup is advancing a trio of multifaceted antibodies with the potential to treat several immune diseases.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.
